Go here to read the rest:
DGAP-News: Cytos Biotechnology Ltd: Convertible bond restructuring proposal approved by the Higher Court of the Canton …

Follow this link:
Monday Sector Leaders: Shipping, Biotechnology Stocks

6 February 2012

Angel Biotechnology Holdings plc.

(“Angel” or “the Company”)

Angel signs three new GMP (KOSDAQ: 018290.KQ – news) manufacturing contracts

for Materia Medica Holding

Angel Biotechnology Holdings plc., (AIM:ABH), the biopharmaceutical contract manufacturer, is pleased to announce that it has reached agreement on three further manufacturing contracts with OOO ” NPF “Materia Medica Holding” (MMH) with a combined value in excess of £4.5 million. It is expected these projects will run concurrently and take approximately 22 months to complete.

Under the proposed agreements, Angel will initiate activities within existing facilities, with a view to transferring production to its Cramlington site during 2012, which the Company is currently re-commissioning. The commission of these new agreements will come under the terms of our current umbrella pricing agreement, pending formation of the joint venture company (“JVC”) announced on 17 October 2011 after which the contracts will transfer into the control of the JVC.

Dr Paul Harper, Executive Chairman, Angel Biotechnology Holdings, said:

“The commission of these three new agreements provides a robust basis for the proposed JVC between Angel and MMH and demonstrates the confidence the customer has in Angel's capabilities. These agreements will put the proposed JVC on a sure footing from the outset, but is also an excellent example of the value Angel can provide via significant alliances such as this.. I would like to thank MMH for making this commercial commitment.”

Professor Oleg Epstein, General Director, OOO “NPF “Materia Medica Holding”, said:

“By signing these three new agreements with Angel, MMH can act in a timely manner to bring these products to market. As core business, it is important to us that development work begins whilst the JVC is being established. I am positive this will provide the best possible start to the new JVC.

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Commercial Director www.angelbio.com

Grant Thornton, Corporate Finance

Colin Aaronson / Melanie Frean / Elliot Berg +44 (0) 20 7383 5100

Hybridan LLP (Broker)

Claire Noyce/Tim Goodman/

Deepak Reddy +44 (0) 20 7947 4350

Media (Frankfurt: 725292 – news) enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

ariane.comstive@communications-portfolio.co.uk

Notes to Editors:

Angel Biotechnology Holdings plc. is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specialises in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.

Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines (Xetra: 938858 – news) and Healthcare products Regulatory Agency (MHRA).

Its (Euronext: ALITS.NX – news) customers range from early-stage biotechnology companies including ReNeuron plc. and US-based Pathfinder Cell Therapy, to established pharmaceutical companies such as Russian-based Materia Medica Holdings.

Angel has two facilities: Pentlands Science Park near Edinburgh where it employs 38 people, and a site in Cramlington, near Newcastle (Frankfurt: 725198 – news) -upon-Tyne, which is expected to be commissioned by the end of Q1 2012, initially employing up to 10 people.

More information is available at www.angelbio.com .

– Ends –

See the rest here:
Angel Biotechnology – Contracts with Materia Medica

www.youtube.com/watch?v=Nb0p9BDZN2U

More here:
Feed 8 Billion – a Panel Discussion on Biotechnology in Agriculture part 1 – Video

Continue reading here:
RBCC: Biotech Industry on Major Upswing in 2012

www.youtube.com/watch?v=jcbqeslTvWQ

More here:
AcrivaUD Reviol Toric T MFM 611 IOL Implantation – VSY Biotechnology – Video

Read the original:
'Yellow biotechnology': Using plants to silence insect genes in a high-throughput manner

DUBLIN–(BUSINESS WIRE)–

Research and Markets (http://www.researchandmarkets.com/research/9636f0/international_dire) has announced the addition of the “International Directory of Biotechnology Companies 2012″ directory to their offering.

The International Directory of Biotechnology Companies 2012 is one of the most comprehensive and accurate Directory of companies and executives in the biotechnology industry that have ever been published. It contains more than 3,000 biotechnology companies and 10,000 executives working in the industry around the world.

This powerful Directory is your connection to key decision-makers in the biotechnology industry in Europe, the Americas, the Asia & Pacific region, the Middle East and Africa.

No other international directory keeps you abreast of the thousands of personnel changes taking place due to company mergers, acquisitions, consolidations, and staff turnover. This Directory is a must-have for anyone who needs to find contacts in the biotechnology sector worldwide.

This Directory will enable you to:

Pinpoint key executives Profile a market Build new business prospects Generate new customers Discover who your competitors are Make vital contacts Save the time, money and effort of doing your own research Identify alternative suppliers and manufacturers Source up-to-date company information Keep track of key staff movements Access a wealth of quality information on companies and key personnel worldwide.

Whether you are a product manager, in charge of marketing or simply interested to remain in touch with the latest developments in the biotechnology industry, this Directory will save you time and effort in finding the up-to-date information you need.

Company categories include in this Directory include:

Biotechnology Genomics Biopharmaceuticals Gene Mapping Bioinformatics Gene Sequencing Biochips Pharmacogenomics & SNP's Functional Genomics plus many more categories!

Key Features of the Directory include:

3,000 biotechnology companies listed with description of company activities 10,000 senior biotechnology personnel listed with name & job title Full contact details including email and website addresses Global coverage of companies and key personnel Comprehensive Indexing

This Directory has been especially compiled to assist biotechnology professionals with market research, strategic planning, as well as contacting prospective clients or suppliers. It is also an indispensable guide to all of the world's biotechnology companies and key biotechnology decision makers!

For more information visit http://www.researchandmarkets.com/research/9636f0/international_dire

Read more from the original source:
Research and Markets: International Directory of Biotechnology Companies 2012: a must-have for anyone who needs to …

www.youtube.com/watch?v=R1Rwrppnf8c

Read the rest here:
Biotechnology Workshop for School Students at Dr. MGR University – Video

WASHINGTON–(BUSINESS WIRE)– The Biotechnology Industry Organization (BIO) announces plenary sessions, Business Roundtables and Therapeutic Workshops selected for the 14th Annual BIO CEO & Investor Conference. Experts chosen to speak on these panels represent leading clinical practitioners, investment professionals, industry analysts and senior biotechnology executives. The conference, to be held February 13-14, 2012 in New York City, is the largest independent investor conference focused on established and publicly-traded biotechnology companies.

“Marked by several M&A transactions, development deals and FDA approvals, 2012 has already been an eventful year in biotech. This year’s program will delve into some of the therapeutic and business catalysts driving positive activity in the biopharma industry,” said Alan Eisenberg, Executive Vice President, Emerging Companies & Business Development at BIO. “The regulatory and financial challenges faced by our industry highlight the need for an independent forum where top industry executives and investment professionals can convene to discuss innovative deal structures and financing mechanisms.”

The BIO CEO & Investor Conference plenary sessions will cover the economic and business issues facing the biotech industry. The Business Roundtables will focus on biotech drug launches, unique business models and licensing and deal making. Therapeutic Workshops will address topics such as oncology, companion diagnostics, neurological and cardiovascular diseases.

Plenary sessions include:
Opening Plenary: Picks and Pans – The Buy-Side View for 2012
Monday, February 13th, 12:00 pm – 12:55 pm

Moderator: Stephen Sands, Vice Chairman of US Investment Banking and Global Co-Head of Healthcare, Lazard
Panelists:

Alexander J. Denner, PhD, (former) Managing Director, Icahn Associates Rajiv Kaul, Portfolio Manager, Fidelity Select Biotechnology Portfolio, Fidelity Greg Martinez, Portfolio Manager, Harbor Watch Capital Management LLC

Luncheon Plenary: Business Development: Value Drivers Under the Influence – How Licensing and Key Events Affect Valuation
Tuesday, February 14th, 12:00 pm – 12:55 pm

Moderator: Ben Bonifant, Senior Vice President and Practice Area Leader, Campbell Alliance
Panelists:

Rachel K. King, Chief Executive Officer, GlycoMimetics, Inc. Michael Margolis, RPh, Managing Director, Healthcare Investment Banking, ROTH Capital Partners Barbara Yanni, JD, LLM, CLP, Vice President and Chief Licensing Officer, Merck & Co

Closing Plenary: Inside the FDA
Tuesday, February 14th, 4:00 pm – 5:00 pm

Moderator: James C. Greenwood, President & CEO, Biotechnology Industry Organization (BIO)
Panelists:

Paul J. Hastings, President & CEO, OncoMed Pharmaceuticals, Inc. Jonathan S. Leff, Managing Director, Healthcare, Warburg Pincus, LLC Richard Pops, Chairman & CEO, Alkermes plc Stephen P. Spielberg, MD, PhD, Deputy Commissioner for Medical Products & Tobacco, FDA

Business Roundtables include:
Business Roundtable: Corporate Strategy
Walking the Line – Finding a Happy Medium between Management and Shareholders
Monday, February 13th, 9:00 am – 9:55 am

Moderator: Annette Grimaldi, Managing Director, BMO Capital Markets
Panelists:

Tillman U. Gerngross PhD, Co-Founder & CEO, Adimab, Inc. Peter Kolchinsky, PhD, Portfolio Manager, RA Capital Management Steven Tregay, PhD, Founder, President & CEO, Forma Therapeutics Steve Worland, PhD, President & CEO (former), Anadys Pharmaceuticals, Inc.

Business Roundtable: Finance
Healthy Alternatives: Non-Dilutive Financing Mechanisms that Sustain Companies
Monday, February 13th, 3:00 pm – 3:55 pm

Moderator: Dean Colucci, President & General Counsel, MLV & Co
Panelists:

Luke M. Beshar, CPA, Sr. Vice President & Chief Financial Officer, NPS Pharmaceuticals Inc. John R. Leone, Partner, Healthcare, Paul Capital Ivana Magov?evi?-Liebisch, PhD, JD. Executive Vice President and Chief Business Officer Russell H. Plumb, MBA, President & Chief Executive Officer, Inhibitex Inc.

Business Roundtable: Corporate Development
Countdown to Launch – Getting it Right the First Time
Tuesday, February 14th, 9:00 am – 9:55 am

Moderator: William Ho, Public Investment Director, New Leaf Venture Partners
Panelists:

Pedro Lichtinger, President & CEO, Optimer Pharmaceuticals Timothy P. Walbert, Chairman, President & Chief Executive Officer, Horizon Pharma, Inc.

Therapeutic Workshops include:
Therapeutic Workshop: Oncology
Secrets of Oncology Success – Lessons and Trends in Phase II Clinical Trial Outcomes
Monday, February 13th, 10:30 am – 11:25 am

Moderator: Michael G. King, Jr., Managing Director, Rodman & Renshaw, LLC
Panelists:

Mohammad Azab, MD, M Sc, MBA, Chief Medical Officer, Astex Pharmaceuticals Inc. Konstantin H. Dragnev, MD, Hematology/Oncology, Dartmouth-Hitchcock Medical Center Michael M. Morrissey, PhD, President & Chief Executive Officer, Exelixis, Inc. Robert F. Ozols, MD, PhD, Senior Vice President, Fox Chase Cancer Center

Therapeutic Workshop: Neurology
Neurology: “Alz” Well That Ends Well – Settling the Beta – Amyloid Debate
Monday, February 13th, 1:30 pm – 2:25 pm

Moderator: Joshua Schimmer, MD, Managing Director, Biotechnology, Leerink Swann, LLC
Panelists:

Ted T. Ashburn, MD, PhD, Senior Director, Corporate Development, Genzyme Corp Michael Gold, MS, MD, Vice President, Clinical Development & Chief Medical Officer, Allon Therapeutics Inc. Marc L. Gordon, MD, Chief of Neurology, Associate Professor of Neurology and Psychiatry, Zucker Hillside Hospital, Hofstra North Shore-LIJ School of Medicine Hyoung-Gon Lee, PhD, Assistant Professor, Case Western University

Therapeutic Workshop: Diagnostics
Drugs Need Friends Too – Companion Diagnostics and Drug Development
Tuesday, February 14th, 10:30 am – 11:25 am

Moderator: Steve Brozak, President, WBB Securities LLC
Panelists:

Thomas Davis, MD, Senior Vice President & Chief Medical Officer, Celldex Therapeutics, Inc. Joanna C. Horobin, MD, President & CEO, Syndax Pharmaceuticals, Inc. Patrick J. Mahaffy, President and Chief Executive Officer, Clovis Oncology

Therapeutic Workshop: Cardiology
Shot to the Heart – The Race to Conquer Dyslipidemia / Hypercholesterolemia
Tuesday, February 14th, 1:15 pm – 2:10 pm

Moderator: Michael J. Haas, Senior Writer, BioCentury Publications, Inc.
Panelists:

Per Bengtsson, MD, PhD, President & CEO, Kara Bio AB Ram Y. Gordon, MD, Clinical Cardiologist, University of Pennsylvania Mark Sumeray, MD, MS, FRCS, Chief Medical Officer, Aegerion Pharmaceuticals, Inc.

To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit here. Registration is complimentary for qualified investors and credential members of the media.

The BIO CEO & Investor Conference is the largest independent investor conference focused solely on publicly-traded biotechnology companies. Investors attend to network with top biotechnology executives, evaluate fresh investment opportunities, attend candid panel discussions and get an overview of the industry and key issues affecting investments.

BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors. The bank sponsors include: BMO Capital Market, Lazard, Leerink Swann, Stifel Nicolaus Weisel, Rodman & Renshaw, LLC and Roth Capital Partners.

Upcoming BIO Events

BIO Asia International Conference
January 31 – February 1, 2012
Osaka, Japan

BIO CEO & Investor Conference
February 13-14, 2012
New York, NY

BIO IP Counsels Committee Conference
April 16 – 18, 2012
Austin, TX

World Congress on Industrial Biotechnology & Bioprocessing
April 29-May 2, 2012
Orlando, FL

2012 BIO International Convention
June 18-21, 2012
Boston, MA

BIO Business Forum
June 18 – 21, 2012
Boston, MA

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, a multiblog platform and monthly newsletter that aims to create an online biotech community where the the industry can connect to discuss the latest news. Subscribe to BIOtechNOW.

For more information:
Visit http://www.bio.org
Follow us on Twitter @IAmBiotech
Join us on LinkedIn/MyBio
Become a fan at facebook.com/IAmBiotech

Visit link:
14th Annual BIO CEO & Investor Conference to Highlight 2012 Investment Outlook, New Business Models and Key …

Biotechnology Industry
Organization
1201 Maryland Ave., SW, Ste. 900
Washington, DC, 20024
USA

Press release date: January 25, 2012

BIO Calls on the Administration and
Congress to Embrace Proposals to Unleash the Promise of
Biotechnology

WASHINGTON–BIO President and CEO Jim Greenwood issued
the following statement in response to President Obama's
State of the Union speech:

“We commend President Obama's call for creating an
economy that is 'built to last.' We strongly believe that
biotechnology can meet this challenge. Our industry
sustains and creates high-wage, high-value U.S. jobs,
fuels 21st century manufacturing and helps drive U.S.
leadership in competitiveness and innovation. Most
importantly, biotechnology offers lifesaving and
innovative scientific breakthroughs through the
development of new cures and treatments for debilitating
diseases including cancer, Multiple Sclerosis and
HIV/AIDS and by providing cutting-edge technologies to
address pressing concerns in creating alternative energy
sources, combating hunger, and protecting against
bio-terror.

“Increasing investment in federally funded research, as
the President called for in his address, is important. It
takes public and private companies to translate that
research into cures and useful technologies. We look
forward to working with the Administration and the
Congress to pursue public policies that will unleash the
promise of biotechnology.

“Curing diseases, first and foremost, means saving lives.
But it also means reducing health care costs. With
science-based regulatory systems, appropriate tax policy
and incentives to encourage continued innovation,
America's biotechnology sector can help drive substantial
job growth in the United States and advance our nation's
competitiveness over the long term. The proposals
detailed in our 'Unleashing the Promise of Biotechnology'
plan are designed to transform the innovative ideas of
today into the realities of tomorrow.

“The President has been a supporter of building a strong
biobased economy. The U.S. biobased economy is growing in
large part from the innovation and commercial development
of the industrial biotechnology sector. Biorefineries
that deploy biotechnology to convert renewable
agricultural feedstocks and other organic raw material to
chemicals and biofuels or more cleanly manufacture
consumer products can help revitalize U.S. manufacturing
and generate high-quality jobs. Growth of the bioeconomy
can strengthen our nation's economic security and energy
security by reducing dependence on foreign oil. And it
could improve the health of our nation's citizens and its
environmental health through more efficient
manufacturing.

“America is the world leader in biotechnology. Our
nation's biotechnology industry is comprised of
scientists, entrepreneurs, and large and small companies
in all 50 states engaged in translating the latest
scientific discoveries into innovative new medical
therapies and environmental products, increased
agricultural production and farm incomes, and greener
bio-based products and biofuels. Nationwide, our industry
directly employs more than 1.4 million people and
indirectly generates jobs for an additional 6.6 million
people. These are high-quality jobs, paying substantially
more than the average U.S. wage.

“Realizing the promise of biotechnology requires a
comprehensive national strategy that fine-tunes some
policies and overhauls others. The biotechnology sector
continues to stand ready to work with President Obama,
his Administration and the Congress to help create jobs
and drive economic growth.”

About BIO
BIO represents more than 1,100 biotechnology companies,
academic institutions, state biotechnology centers and
related organizations across the United States and in
more than 30 other nations. BIO members are involved in
the research and development of innovative healthcare,
agricultural, industrial and environmental biotechnology
products. BIO also produces the BIO International
Convention, the world's largest gathering of the
biotechnology industry, along with industry-leading
investor and partnering meetings held around the world.
BIO produces BIOtech NOW, an online portal and monthly
newsletter chronicling “innovations transforming our
world.” Subscribe to BIOtech NOW.

View post:
Biotechnology Can Provide Foundation for a U.S. Economy "Built To Last"

SEATTLE, WA–(Marketwire -01/30/12)- Plandaí Biotechnology,
Inc. (OTC.BB:
PLPL.OB –
News) Chief Executive Officer, Roger Duffield, today
announced that Dr. Tom Matula has accepted the position of
Chairman of the Scientific Board for Plandaí Biotechnology,
Inc., effective immediately.

Dr. Matula is a world-renowned scientist and entrepreneur with
expertise in medical and industrial applications of ultrasound.
He is the author of over 40 peer-reviewed publications and has
several patents in the medical devices landscape. Dr. Matula is
a past winner of the Department of Defense Young Scientist
Award and was also awarded the Presidential Early Career Award,
the highest honor bestowed by the United States government on
science and engineering professionals in the early stages of
their careers. He has advised members of congress on energy
issues, and helps organize panels on technology transfer out of
universities.

Dr. Matula received his PhD. in Physics from Washington State
University. He currently serves as Affiliate Associate
Professor, Bioengineering and Electrical Engineering with the
University of Washington, is the Director of the Center for
Industrial and Medical Ultrasound and the Director of the
Center for Ultrasound-based Molecular Imaging and Therapy, both
with the University of Washington. Dr. Matula also serves as
Principal Physicist with the Applied Physics Laboratory at the
University of Washington.

Dr. Matula is a co-inventor of Plandaí Biotechnology's
proprietary technology that extracts a high level of
bio-available compounds from organic matter including green tea
leaves and most other organic materials. Various tests have
been conducted over the past ten years using this technology
that generates functional chemical compounds possessing
nutritive properties that act effectively as preventive agents
in the healthcare field. Polyphenols from green tea are an
excellent source of antioxidant and anti-carcinogenic
substances. Dr.Matula has been instrumental in bringing this
technology to market through Plandaí Biotechnology.

Mr. Duffield commented, “Plandaí is delighted that Dr. Matula
has accepted the chair position as we have been working
together on the science behind our company for over 10 years.
As a scientist, he brings a wealth of experience and insight as
we transition from research into market-ready products. Plandaí
Biotechnology intends to continue adding highly qualified and
experienced professionals to our Scientific Advisory Board. Dr.
Matula's leadership as the Chairman of our Scientific Board
demonstrates the acceptance within the scientific community of
our technology.”

Additional information on Dr. Matula's background can be found
at:

http://www.apl.washington.edu/people/profile.php?last=Matula&first=Tom.

About Plandaí Biotechnology, Inc.

Plandaí Biotechnology, Inc., through its recent acquisition of
Global Energy Solutions, Ltd. and its subsidiaries, focuses on
the farming of whole fruits, vegetables and live plant material
and the production of proprietary functional foods and
botanical extracts for the health and wellness industry. Its
principal holdings consist of land, farms and infrastructure in
South Africa.

Visit link:
Plandai Biotechnology, Inc. Announces Appointment of World-Renowned Physicist to Chair Plandai Scientific Board

Read the original:
Inovio Pharmaceuticals and Keryx Biopharmaceuticals Benefit From Strengthening Biotech Sector

See the rest here:
Boost in Biotech Funding Benefits CEL-SCI and Human Genome Sciences

Go here to read the rest:
Plandai Biotechnology, Inc. Announces $13 Million in New Financing

Read the original:
Biotechnology Can Provide Foundation for a U.S. Economy “Built To Last”

Read this article:
Biotechnology Industry on the Upswing — Aeterna Zentaris and Elite Pharmaceuticals to Benefit

www.youtube.com/watch?v=r7aPbu3b5dk

Go here to see the original:
SCF Biotechnology Program – Video

See the original post:
Lando & Anastasi, LLP Expands Chemical/Materials, Biotechnology/Pharmaceutical, and Electrical/Computer Patent Teams